Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

Table 4 Efficacy of cytopenia combined with Intraperitoneal hyperthermic chemotherapy to observe the survival of patients with peritoneal pseudomyxoma with different clinical features

Variable	Cases	5-year OS (%)	95%CI (%)	P value
Age (years)				0.480
Up to 60	121	48.7	36.9-60.5
Greater than 60	65	54.2	37.9-70.5
Gender				0.139
Male	65	41.8	26.1-57.5
Female	121	55.4	43.6-67.2
Primary site				0.701
Appendix	170	50.6	40.6-60.6
Ovary	15	49.5	16.8-82.2
Other	l
Pathological level				< 0.00
Low-level	99	68.1	54.8-81.4
High level	57	26.3	11.0-41.6
Lymph node metastasis				0.107
Correct	19	54.3	27.8-80.8
Deny	151	49.4	39.2-59.6
Suspicious transfer	16	66.7	13.4-100.0
Peritoneal tumor index score (points)			0.001	0.001
≤ 20	41	82.1	67.4-96.8
21-39	111	44.0	30.5-57.5
CCR score				< 0.001
CCR-0	15	88.9	68.3-100.0
CCR-1	40	77.6	62.7-92.5
CCR-2/3	113	42.0	29.5-54.5
Whether to combine organ resection				0.915
Correct	123	46.3	32.8-59.8
Deny	63	54.7	40.8-68.6
HIPEC treatment plan				0.597
Raltitrexed	47	67.7	51.4~84.0
Oxaliplatin + Letotrexate + Mitomycin	42	50.8	23.8~77.8
Platinum	32	40.2	21.4-59.0
Oxaliplatin + Letotrexate	25	30.0	9.0-51.0
Letotrexate + Mitomycin	20	100
Mitomycin	8	50.0	10.0-90.0
Oxaliplatin + Mitomycin	8	37.5	4.0-71.0
Other	4	50.0	1.0-99.0

HIPEC: Intraperitoneal hyperthermic chemotherapy; CCR: Cell reduction degree; OS: Overall survival.